로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Antibody > Bevacizumab > BEB-Y12

Anti-Bevacizumab Antibody (AY12) (recommended for neutralizing assay)

  • Source
    Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Bevacizumab F(ab')2.
  • Isotype
    Mouse IgG1/kappa
  • Specificity
    Recognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
SDS-PAGE
Bevacizumab SDS-PAGE

Anti-Bevacizumab Antibody (AY12) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-Elisa
 Bevacizumab ELISA

Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 5 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 62 ng/mL.

 Bevacizumab ELISA

Demonstration of the specificity of Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12) to the bevacizumab.

 Bevacizumab ELISA

Measured by its neutrlizing ability in a functional ELISA. Immobilized bevacizumab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12) and Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a inhibition rate of 96%.

Bioactivity-SPR
 Bevacizumab SPR

Anti-Bevacizumab Antibody (AY12) (mouse IgG1, Cat. No. BEB-Y12) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 0.08 nM.

  • Background
    A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 450,000

가격(KRW) : 3,270,000

보급 및 전시



Datasheet & Documentation

DMF 신청
DMF (Drug Master File)

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop